Dr. Cheng of Morningside focuses on life science and technology investments. Prior to joining Morningside, Dr. Cheng was Director of Research and Development at Serica Technologies, a Morningside portfolio company. In addition, Dr. Cheng was previously an Associate Director at Novartis Pharmaceuticals in Clinical Development and Medical Affairs.
Dr. Cheng received his M.D. from Tufts University School of Medicine. He is the recipient of numerous honors and awards including the Howard Hughes Medical Institute Research Fellowship, which supported his research under Dr. Rudy Tanzi in the Genetics and Aging Unit of the Massachusetts General Hospital / Harvard Medical School. He has worked with many startups and currently sits on the Board of Directors of Traversa Therapeutics and is a board observer to Argos Therapeutics.